Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a U.S.-based early-stage biotechnology company developing next-generation brain-penetrant allosteric small molecules through its Magellan™ computational platform. Its lead clinical candidate, GT-02287, is being advanced for Parkinson’s disease and other neurodegenerative disorders, while the company also pursues discovery, preclinical work, and partnering opportunities around its platform technology.

6.63

— Gain Therapeutics, Inc.
	%
Clinical-stage drug candidate	0% Lead therapeutic program being advanced through clinical development for neurodegenerative disease.
Preclinical discovery pipeline	0% Earlier-stage small-molecule programs generated from the company’s discovery efforts.
Computational discovery platform	0% Magellan™ identifies novel allosteric binding sites and potential drug candidates.
Partnering and licensing	100% Collaborations and licensing arrangements that monetize platform technology and know-how.

The company’s direct counterparties are pharmaceutical and biotechnology partners that may license or co-develop...

Pharmaceutical and biotech partnersprimary
Buy access to platform-enabled discovery, licensing, or co-development rights to accelerate pipeline creation.
Clinical development stakeholdersprimary
Regulators, investigators, and trial sites that support advancement of GT-02287 and future candidates.
Future patients and prescribersemerging
Would use approved therapies for Parkinson’s disease and other neurodegenerative conditions.

Gain Therapeutics is headquartered in the United States and operates as a U.S.-listed development-stage biotech...

•Headquartered in the United States
•Clinical and regulatory activities are centered on U.S. development
•Materials for product candidates are currently manufactured in China
•Potential future commercialization would likely be multi-region
•No disclosed country revenue because the company has no product sales

The company’s strategy is to advance GT-02287 and other Magellan™-derived programs through preclinical and clinical...

Advance clinical-stage lead programshort-term

Clinical progress is the main source of value creation and partnering leverage.

Secure non-dilutive or strategic fundingshort-term

The company has no product revenue and needs capital to fund development.

Broaden platform applicationsmedium-term

A wider target set can increase the probability of partnering and future pipeline value.

Gain Therapeutics faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need...

critical

Clinical development failure

Lead programs may not demonstrate sufficient safety or efficacy to advance.

Scope: GT-02287 and future pipeline candidates
Materiality: high

critical

Financing shortfall

The company expects continued losses and negative operating cash flow.

Scope: R&D, trials, and general corporate operations
Materiality: high

high

Regulatory delay or non-approval

FDA, EMA, or other agencies can slow or block development and commercialization.

Scope: Clinical-stage product candidates
Materiality: high

high

China sourcing and tariff exposure

APIs and other materials are currently manufactured in China, increasing cost and supply risk.

Scope: Clinical supply chain and future manufacturing
Materiality: high

Research and development expense accruals

Can shift quarterly operating loss and liabilities

Stock-based compensation

Affects operating expenses and comparability across periods

Research grant recognition

Can reduce net loss or offset R&D expense

Collaboration and licensing accounting

Could materially affect revenue timing if deals are signed

Gain Therapeutics, Inc.

Clinical development failure

Financing shortfall

Regulatory delay or non-approval

China sourcing and tariff exposure

Voyager Therapeutics, Inc.

Serina Therapeutics, Inc.

Marker Therapeutics, Inc.

MapLight Therapeutics, Inc.

GT Biopharma, Inc.

Neurogene Inc.